microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients.

microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients. Asian Pac J Cancer Prev. 2019 08 01;20(8):2379-2383 Authors: Mirza MAB, Guru SA, Abdullah SM, Rizvi A, Saxena A Abstract Background: Chronic myeloid leukaemia (CML) is a myeloproliferative disorder categorized by malignant transformation of a single stem cell of hematopoietic cells. microRNAs (miRNAs) belong to transcription regulators in hematopoiesis and their altered expression associates with pathogenesis of CML. Aim: Current study aimed to access the miR-21 expression profile in CML patients and therapy response as well as its prognostic significance. Methods: 100 CML cases, 100 controls were included in study and miR-21 expression was analyzed. Overall 9.22 mean fold increased expression was observed in CML patients before treatment. Results: Patients with different CML phases such as chronic phase, accelerated phase and blast crisis showed 7.16, 10.30 and 13.20 fold increased expression respectively. Overall 3.57 mean fold expression was observed in imatinib treated patients suggested more than 5 fold decreased expression in CML patients. Prognostic significance was calculated and observed that miR-21 expression at 7.29 fold cutoff, 75% sensitivity and 50% specificity was observed (AUC=0.75, p
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research

Related Links:

Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and d...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Acute Bilineal Leukemia;   Minimal Residual Disease;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloproliferative Neoplasm;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positiv...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are complex clonal hematopoietic stem cell malignancies with overlapping dysplastic and proliferative features. Genomic analyses have charted the somatic mutation spectrum of MDS/MPN and revealed a major role for epigenetic dysregulation in their pathogenesis. No disease-modifying therapies are currently available, as progress has been hampered by a lack of genetically faithful in vivo model systems suitable for the preclinical development of new strategies. Yoshimi et al (Blood. 2017;130:397-407) recently showed that patients' chronic myelomonocytic leukemia (CMML) an...
Source: Blood - Category: Hematology Authors: Tags: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster I Source Type: research
Conclusion.We show that both mouse and human MPNs have higher Dusp1 expression irrespective of MPN drivers (JAK2, MPL, and CALR). Jak2V617F is uniquely addicted to the Dusp1 expression, where genetic deletion of Dusp1 is lethal to Jak2V617F expressing cells, but not to the other MPN drivers, such as, MPLW515L. Thus, providing a rationale for targeting the Dusp1 in Jak2 mutated MPNs to eliminate the mutant clones and cure the disease.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 635. Myeloproliferative Syndromes: Basic Science: Identification of Novel Therapeutic Targets Source Type: research
Publication date: Available online 31 July 2018Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Hemanth Naick Banavath, Srinivasa Rao Allam, Stella Sravanthi Valathati, Alok Sharan, Baskaran RajasekaranAbstractChronic myelogenous leukemia (CML) is a myeloproliferative disorder occurs in the pluripotent hematopoietic stem cell. Currently, first-generation tyrosine kinase inhibitor (TKI) imatinib is the mainstay for the treatment of CML. Second generation TKI's like ponatinib, dasatinib, nilotinib, and bafetinib were treated against resistant CML. However, several CML patients develop resistance toward...
Source: Journal of Photochemistry and Photobiology B: Biology - Category: Speech-Language Pathology Source Type: research
Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. Wien Klin Wochenschr. 2018 Jul 13;: Authors: Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C Abstract In 2008 the Ludwig Boltzmann Cluster Oncology (LBC ONC) was established on the basis of two previous Ludwig Boltzmann Institutes working in the field of hematology and cancer research. The gene...
Source: Wiener Klinische Wochenschrift - Category: General Medicine Authors: Tags: Wien Klin Wochenschr Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Myeloproliferative Disorders | Stem Cell Therapy | Stem Cells | Study